Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
VRTX
VRTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VRTX News
Vertex Achieves Phase 3 Trial Success, Boosting Stock Performance
8h ago
Benzinga
U.S. Markets Closed with Mixed Results on Tuesday, Driven by BridgeBio Pharma's Gains and Centene's Declines
2h ago
Barron's
CRISPR Therapeutics to Issue $350 Million Convertible Notes
5h ago
Benzinga
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
5h ago
CNBC
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
6h ago
CNBC
U.S. Stocks Rise as NIO Reports Strong Earnings
6h ago
Benzinga
Vertex's Drug Success in Phase 3 Trial Paves Way for Kidney Disease Expansion
6h ago
Newsfilter
Centene Shares Drop 7.7%, Worst Performer in S&P 500 Today
7h ago
NASDAQ.COM
Kohl's Q4 Revenue Misses Expectations, Casey's Revenue Declines
9h ago
CNBC
Top Rule Breakers Seek Innovation
10h ago
Fool
S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead
10h ago
Barron's
Key Stock Market Movers: Occidental, Vertex, HPE, TSMC, Oracle, and Others
12h ago
Barron's
Vertex Announces Kidney Drug Trial Results and Their Implications for Stock Performance.
12h ago
Barron's
Vertex Shares Surge: Insights from Wall Street on Its Kidney Drug Trial.
12h ago
Barron's
Stock Futures Rise as Oil Prices Rebound Amid War Easing Narrative
13h ago
seekingalpha
Vertex Pharmaceuticals Reports Positive Phase 3 Trial Results for IgAN Treatment
13h ago
seekingalpha
Show More News
